Galmed Pharmaceuticals (GLMD) Competitors $1.81 -0.04 (-2.16%) Closing price 04:00 PM EasternExtended Trading$1.81 0.00 (0.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. PHXM, AIMD, BTAI, CLDI, GLYC, CYCN, ERNA, TLPH, BCLI, and APREShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include PHAXIAM Therapeutics (PHXM), Ainos (AIMD), BioXcel Therapeutics (BTAI), Calidi Biotherapeutics (CLDI), GlycoMimetics (GLYC), Cyclerion Therapeutics (CYCN), Eterna Therapeutics (ERNA), Talphera (TLPH), Brainstorm Cell Therapeutics (BCLI), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Its Competitors PHAXIAM Therapeutics Ainos BioXcel Therapeutics Calidi Biotherapeutics GlycoMimetics Cyclerion Therapeutics Eterna Therapeutics Talphera Brainstorm Cell Therapeutics Aprea Therapeutics Galmed Pharmaceuticals (NASDAQ:GLMD) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends. Which has preferable valuation & earnings, GLMD or PHXM? PHAXIAM Therapeutics has higher revenue and earnings than Galmed Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.11PHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Does the media prefer GLMD or PHXM? In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Galmed Pharmaceuticals and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.59 beat Galmed Pharmaceuticals' score of 0.00 indicating that PHAXIAM Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Galmed Pharmaceuticals Neutral PHAXIAM Therapeutics Positive Do institutionals and insiders have more ownership in GLMD or PHXM? 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer GLMD or PHXM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GLMD or PHXM more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -32.21% -28.59% PHAXIAM Therapeutics N/A N/A N/A Which has more risk & volatility, GLMD or PHXM? Galmed Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. SummaryPHAXIAM Therapeutics beats Galmed Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06M$2.44B$5.42B$8.73BDividend YieldN/A1.65%5.37%4.21%P/E Ratio-0.113.9717.8819.16Price / SalesN/A517.47404.46112.14Price / CashN/A151.9635.9456.46Price / Book0.184.857.985.50Net Income-$7.52M$31.15M$3.14B$248.18M7 Day Performance1.69%2.89%0.89%0.76%1 Month Performance30.22%12.46%5.18%4.44%1 Year Performance-52.57%3.91%37.53%16.92% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals0.3644 of 5 stars$1.81-2.2%N/A-51.7%$3.06MN/A-0.1120Gap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AIMDAinos0.8986 of 5 stars$0.50-0.1%N/A-40.4%$10.46M$106.21K-0.3940News CoverageBTAIBioXcel Therapeutics4.0302 of 5 stars$1.69+8.3%$42.60+2,420.7%-90.9%$10.24M$1.85M-0.0590Analyst RevisionGap UpCLDICalidi Biotherapeutics1.6737 of 5 stars$0.32-7.2%$10.00+3,025.0%N/A$10.17M$50K0.0038Gap DownGLYCGlycoMimetics1.1571 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450News CoverageHigh Trading VolumeCYCNCyclerion Therapeutics0.7615 of 5 stars$3.11-0.2%N/A+15.8%$9.97M$2.08M-2.6830Positive NewsERNAEterna Therapeutics0.9757 of 5 stars$2.39+4.4%N/A-92.9%$9.94M$535K-0.2910News CoverageTLPHTalphera1.7386 of 5 stars$0.48-1.8%$5.00+939.5%-51.4%$9.86M$27K-0.7019Positive NewsBCLIBrainstorm Cell Therapeutics3.6735 of 5 stars$1.24+12.7%$30.00+2,319.4%-78.4%$9.84MN/A-0.2640Gap UpHigh Trading VolumeAPREAprea Therapeutics2.9382 of 5 stars$1.77-3.8%$15.50+775.7%-60.7%$9.79M$580K-0.637News Coverage Related Companies and Tools Related Companies PHXM Competitors AIMD Competitors BTAI Competitors CLDI Competitors GLYC Competitors CYCN Competitors ERNA Competitors TLPH Competitors BCLI Competitors APRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
